Shots: Bausch + Lomb has received the US FDA’s approval for Lumify Preservative Free eye drops to treat ocular redness due to minor eye irritations The studies demonstrated low incidence of side effects such as rebound redness and loss of efficacy over time with Lumify Preservative Free eye drops. The company plans its availability in…

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023

Shots:The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's DiseasePharmaShots has…

BySenior EditorJune 21, 2023

Bausch + Lomb’s Lumify Receives the US FDA’s Approval to Treat Ocular Redness

Insights+: The US FDA New Drug Approvals in May 2023

Contact US

OUR INFORMATION

FOLLW US

Bausch + Lomb’s Lumify Receives the US FDA’s Approval to Treat Ocular Redness

Insights+: The US FDA New Drug Approvals in May 2023

FOLLW US

Sign Up to Our Newsletter